Hypoxia-driven cell motility reflects the interplay between JMY and HIF-1α

Oncogene

Volumn 30, Issue 48, 2011, Pages 4835-4842

  Coutts, A S ^a   Pires, I M ^b   Weston, L ^a   Buffa, F M ^a   Milani, M ^a   Li, J L ^a   Harris, A L ^a   Hammond, E M ^b   La Thangue, N B ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Actin; HIF 1; Hypoxia; JMY; Motility

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR JMY; UNCLASSIFIED DRUG;

ARTICLE; CELL INVASION; CELL MOTILITY; CONTROLLED STUDY; HUMAN; HUMAN CELL; HYPOXIA; PRIORITY JOURNAL; PROMOTER REGION; UPREGULATION;

BASE SEQUENCE; CELL HYPOXIA; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MOLECULAR SEQUENCE DATA; NUCLEAR PROTEINS; PROMOTER REGIONS, GENETIC; TRANS-ACTIVATORS;

EID: 82455209030     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.188     Document Type: Article

References (25)

1. Biswas S, Troy H, Leek R, Chung YL, Li JL, Raval RR et al. (2010). Effects of HIF-1alpha and HIF-2alpha on growth and metabolism of clear-cell renal cell carcinoma 786-0 xenografts. J Oncol 2010: 757908.
2. Chan HM, Krstic-Demonacos M, Smith L, Demonacos C, La Thangue NB. (2001). Acetylation control of the retinoblastoma tumour-suppressor protein. Nat Cell Biol 3: 667-674. (Pubitemid 32624423)
3. Coutts AS, Boulahbel H, Graham A, La Thangue NB. (2007). Mdm2 targets the p53 transcription cofactor JMY for degradation. EMBO Rep 8: 84-90. (Pubitemid 46043805)
4. Coutts AS, Weston L, La Thangue NB. (2009). A transcription cofactor integrates cell adhesion and motility with the p53 response. Proc Natl Acad Sci USA 106: 19872-19877.
5. Dang DT, Chen F, Gardner LB, Cummins JM, Rago C, Bunz F et al. (2006). Hypoxia-inducible factor-1alpha promotes nonhypoxiamediated proliferation in colon cancer cells and xenografts. Cancer Res 66: 1684-1936.
6. Demonacos C, Krstic-Demonacos M, La Thangue NB. (2001). A TPR motif cofactor contributes to p300 activity in the p53 response. Mol Cell 8: 71-84. (Pubitemid 32772906)
7. Erler JT, Bennewith KL, Nicolau M, Dornhofer N, Kong C, Le QT et al. (2006). Lysyl oxidase is essential for hypoxia-induced metastasis. Nature 440: 1222-1226.
8. Ferrara N, Hillan KJ, Novotny W. (2005). Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy. Biochem Biophys Res Commun 333: 328-335. (Pubitemid 40848295)
9. Harris AL. (2002). Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47. (Pubitemid 37328806)
10. Jansson M, Durant ST, Cho EC, Sheahan S, Edelmann M, Kessler B et al. (2008). Arginine methylation regulates the p53 response. Nat Cell Biol 10: 1431-1439.
11. Kaelin Jr WG, Ratcliffe PJ. (2008). Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol Cell 30: 393-402. (Pubitemid 351681994)
12. Krishnamachary B, Zagzag D, Nagasawa H, Rainey K, Okuyama H, Baek JH et al. (2006). Hypoxia-inducible factor-1-dependent repression of E-cadherin in von Hippel-Lindau tumor suppressornull renal cell carcinoma mediated by TCF3, ZFHX1A, and ZFHX1B. Cancer Res 66: 2725-2731.
13. Lee K, Lee JH, Boovanahalli SK, Jin Y, Lee M, Jin X et al. (2007). (Aryloxyacetylamino)benzoic acid analogues: a new class of hypoxia-inducible factor-1 inhibitors. J Med Chem 50: 1675-1684. (Pubitemid 46564388)
14. Li JL, Sainson RC, Shi W, Leek R, Harrington LS, Preusser M et al. (2007). Delta-like 4 Notch ligand regulates tumor angiogenesis, improves tumor vascular function, and promotes tumor growth in vivo. Cancer Res 67: 11244-11253. (Pubitemid 350248550)
15. Marine JC, Francoz S, Maetens M, Wahl G, Toledo F, Lozano G. (2006). Keeping p53 in check: essential and synergistic functions of Mdm2 and Mdm4. Cell Death Differ 13: 927-934.
16. Rankin EB, Giaccia AJ. (2008). The role of hypoxia-inducible factors in tumorigenesis. Cell Death Differ 15: 678-685. (Pubitemid 351405072)
17. Rapisarda A, Shoemaker RH, Melillo G. (2009). Antiangiogenic agents and HIF-1 inhibitors meet at the crossroads. Cell Cycle 8: 4040-4043.
18. Semenza GL. (2010). Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene 29: 625-634.
19. Shikama N, Lee CW, France S, Delavaine L, Lyon J, Krstic-Demonacos M et al. (1999). A novel cofactor for p300 that regulates the p53 response. Mol Cell 4: 365-376. (Pubitemid 29499789)
20. Spinella F, Rosano L, Di Castro V, Decandia S, Nicotra MR, Natali PG et al. (2007). Endothelin-1 and endothelin-3 promote invasive behavior via hypoxia-inducible factor-1alpha in human melanoma cells. Cancer Res 67: 1725-1734. (Pubitemid 46383399)
21. Sullivan R, Graham CH. (2007). Hypoxia-driven selection of the metastatic phenotype. Cancer Metastasis Rev 26: 319-331. (Pubitemid 47101665)
22. Wang GL, Jiang BH, Rue EA, Semenza GL. (1995). Hypoxiainducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension. Proc Natl Acad Sci USA 92: 5510-5514.
23. Wang GL, Semenza GL. (1993). Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNAbinding activity: implications for models of hypoxia signal transduction. Blood 82: 3610-3615. (Pubitemid 24006041)
24. Zalmas LP, Zhao X, Graham AL, Fisher R, Reilly C, Coutts AS et al. (2008). DNA-damage response control of E2F7 and E2F8. EMBO Rep 9: 252-259. (Pubitemid 351330990)
25. Zuchero JB, Coutts AS, Quinlan ME, La Thangue NB, Mullins RD. (2009). p53-cofactor JMY is a multifunctional actin nucleation factor. Nat Cell Biol 11: 451-459.